Dec 5, 2013 - Cite this article as: Burgos-Vargas, R., Tse, S., Horneff, G. et al. Pediatr Rheumatol (2013) 11(Suppl 2): O14. doi:10.1186/1546-0096-11-S2- ...
Burgos-Vargas et al. Pediatric Rheumatology 2013, 11(Suppl 2):O14 http://www.ped-rheum.com/content/11/S2/O14
ORAL PRESENTATION
Open Access
PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis R Burgos-Vargas1*, S Tse2, G Horneff3, AL Pangan4, K Unnebrink5, JK Anderson4 From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013 Introduction Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the sacroiliac joints and spine. It causes long-term effects on both physical and quality aspects of a child’s life. Adalimumab (ADA) has been previously demonstrated to be effective in polyarticular JIA. Objectives To evaluate the efficacy and safety of adalimumab compared to placebo in children and adolescents with ERA. Methods This is a phase 3, multicenter, randomized, double-blind (DB) study in patients (pts) aged ≥6 to
